1.30
+0(+0.00%)
Currency In USD
| Previous Close | 1.3 |
| Open | 1.32 |
| Day High | 1.33 |
| Day Low | 1.27 |
| 52-Week High | 1.92 |
| 52-Week Low | 0.91 |
| Volume | 402,555 |
| Average Volume | 303,905 |
| Market Cap | 76.8M |
| PE | -2.89 |
| EPS | -0.45 |
| Moving Average 50 Days | 1.35 |
| Moving Average 200 Days | 1.33 |
| Change | 0 |
If you invested $1000 in Vivani Medical, Inc. (VANI) 10 years ago, it would be worth $10.24 as of February 21, 2026 at a share price of $1.3. Whereas If you bought $1000 worth of Vivani Medical, Inc. (VANI) shares 5 years ago, it would be worth $203.44 as of February 21, 2026 at a share price of $1.3.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026
GlobeNewswire Inc.
Jan 29, 2026 12:30 PM GMT
Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also
Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026
GlobeNewswire Inc.
Jan 22, 2026 12:00 PM GMT
Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company’s new Orion cortical stimulation system for visual perception, designed to treat most common forms of blindness, successfully comp
Vivani Medical, Inc. Announces Closing of Common Stock Offering
GlobeNewswire Inc.
Oct 28, 2025 8:05 PM GMT
ALAMEDA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its